A new trading day began on Monday, with BridgeBio Pharma Inc (NASDAQ: BBIO) stock price up 3.56% from the previous day of trading, before settling in for the closing price of $46.58. BBIO’s price has ranged from $21.72 to $49.77 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -3.04% over the past five years. Meanwhile, its annual earnings per share averaged -22.05%. With a float of $161.95 million, this company’s outstanding shares have now reached $191.16 million.
Let’s look at the performance matrix of the company that is accounted for 730 employees. In terms of profitability, gross margin is 96.8%, operating margin of -278.03%, and the pretax margin is -330.59%.
BridgeBio Pharma Inc (BBIO) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of BridgeBio Pharma Inc is 15.28%, while institutional ownership is 83.82%. The most recent insider transaction that took place on Aug 07 ’25, was worth 45,440. In this transaction Chief Accounting Officer of this company sold 1,000 shares at a rate of $45.44, taking the stock ownership to the 141,859 shares. Before that another transaction happened on Aug 08 ’25, when Company’s Chief Executive Officer sold 40,000 for $46.22, making the entire transaction worth $1,848,828. This insider now owns 915,686 shares in total.
BridgeBio Pharma Inc (BBIO) Performance Highlights and Predictions
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -1.08 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.71 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -22.05% per share during the next fiscal year.
BridgeBio Pharma Inc (NASDAQ: BBIO) Trading Performance Indicators
Here are BridgeBio Pharma Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.08. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 39.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.09, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -1.80 in one year’s time.
Technical Analysis of BridgeBio Pharma Inc (BBIO)
BridgeBio Pharma Inc (NASDAQ: BBIO) saw its 5-day average volume 5.47 million, a positive change from its year-to-date volume of 3.06 million. As of the previous 9 days, the stock’s Stochastic %D was 62.93%.
During the past 100 days, BridgeBio Pharma Inc’s (BBIO) raw stochastic average was set at 92.86%, which indicates a significant increase from 80.08% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.81 in the past 14 days, which was higher than the 1.61 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $43.64, while its 200-day Moving Average is $34.44. Nevertheless, the first resistance level for the watch stands at $48.93 in the near term. At $49.62, the stock is likely to face the second major resistance level. The third major resistance level sits at $50.95. If the price goes on to break the first support level at $46.92, it is likely to go to the next support level at $45.59. Assuming the price breaks the second support level, the third support level stands at $44.90.
BridgeBio Pharma Inc (NASDAQ: BBIO) Key Stats
With a market capitalization of 9.22 billion, the company has a total of 191,169K Shares Outstanding. Currently, annual sales are 221,900 K while annual income is -535,760 K. The company’s previous quarter sales were 116,630 K while its latest quarter income was -167,420 K.
